| P50 | author | Eileen L Yoon | Q83964390 |
| P2093 | author name string | Jeong Han Kim | |
| | Ju Hyun Kim | |
| | Yun Soo Kim | |
| | Chang Hong Lee | |
| | Jong Eun Yeon | |
| | Kwan Soo Byun | |
| | So Young Kwon | |
| | Won Hyeok Choe | |
| | Cho I Lee | |
| P2860 | cites work | Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: An international multicenter cohort study | Q58097173 |
| | Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B | Q82240888 |
| | Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B | Q28212394 |
| | Lamivudine, adefovir and tenofovir exhibit long-lasting anti-hepatitis B virus activity in cell culture | Q28373274 |
| | Chronic hepatitis B. | Q34002160 |
| | Lamivudine for patients with chronic hepatitis B and advanced liver disease | Q34551713 |
| | Drug resistance in antiviral treatment for infections with hepatitis B and C viruses | Q36832325 |
| | EASL Clinical Practice Guidelines: management of chronic hepatitis B. | Q37340737 |
| | Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence | Q37857483 |
| | The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains | Q39876916 |
| | In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents | Q40115548 |
| | Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus | Q40262602 |
| | Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir | Q40887887 |
| | Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. | Q42678962 |
| | Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy | Q42957928 |
| | Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection. | Q42989166 |
| | Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice | Q43445015 |
| | Long-term safety of lamivudine treatment in patients with chronic hepatitis B. | Q44729211 |
| | Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations | Q44837960 |
| | Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy | Q45414035 |
| | Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. | Q46217486 |
| | Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. | Q46408081 |
| | Virologic response and resistance to adefovir in patients with chronic hepatitis B. | Q46842950 |
| | Response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir. | Q53664727 |
| | Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. | Q54599747 |
| P433 | issue | 1 | |
| P921 | main subject | tenofovir | Q155954 |
| | chronic hepatitis B | Q55779876 |
| P304 | page(s) | 64-69 | |
| P577 | publication date | 2013-11-05 | |
| P1433 | published in | Gut and liver | Q26841957 |
| P1476 | title | Efficacy and safety of tenofovir-based rescue therapy for chronic hepatitis B patients with previous nucleo(s/t)ide treatment failure | |
| P478 | volume | 8 | |